Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Samaritan Pharmaceuticals has signed an exclusive licensing and distribution agreement with Three Rivers Pharmaceuticals to market Amphocil in Ireland. Amphocil is used for the treatment of invasive aspergillosis, a fungal infection that occurs in immuno-compromised patients.
Subscribe to our email newsletter
Currently, Samaritan has the marketing rights for Amphocil (amphotericin B cholesteryl sulfate) in Greece and Cyprus, and has successfully registered and obtained a price increase for Amphocil in Greece.
Dr Janet Greeson of Samaritan, said: “We are making great strides in making Samaritan a revenue company. The niche territories of Greece and eastern Europe are often overlooked although together the territories account for 300 million people so we see it as an opportunity. Getting an already approved US or European drug launched in our targeted territories takes a special expertise and long term relationships.”
Mr. Greeson also said: “We are fortunate to have built relationships in Ireland through Pharmaplaz, Ireland and we are extremely fortunate to have Dr Christos Dakas as our European director, who has built a long list of credible relationships in Greece and eastern Europe. We give Dr Dakas and Eugene Boyle a lot of credit for their persistence in trying to make Samaritan self sustaining in the future.”